Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05008276

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Puberty is a complex process of physiological changes, including neuroreproductive and growth hormone activation and rapid organ growth, that may predispose organs to injury. The kidneys may be especially susceptible because they are highly metabolically active and second only to the heart with respect to oxygen consumption per tissue mass. During puberty, the kidneys almost double in size, likely increasing the kidneys' already high energy expenditure. In parallel, puberty is associated with physiologic insulin resistance (IR), which is accentuated in obesity. Our central hypothesis is that obese youth with prediabetes and T2D experience relative kidney hypoxia during puberty due to a metabolic mismatch between increased energy expenditure and impaired substrate metabolism. In turn, the kidney hypoxia results in loss of glomerular charge and size selectivity leading to increased transglomerular transport of protein and kidney dysfunction. Our preliminary data showed that pubertal adolescents with obesity and/or diabetes exhibit relative kidney hypoxia compared to normal weight controls using functional magnetic resonance imaging (MRI) and that relative kidney hypoxia is greater in late vs. early puberty. However, determining the pubertal mechanisms contributing to kidney injury in youth with obesity and T2D requires serial evaluations throughout puberty. To assess the impact of pubertal changes within a 5-year study period, the investigators propose an accelerated longitudinal study design in which the investigators will enroll adolescents (8-14 years, 50% girls) with obesity and/or elevated hemoglobin A1c (HbA1c ≥6%) [n=60], and healthy normoglycemic controls [n=40] at Tanner (pubertal) stages 1-4 and examine them at baseline, 1 and 2-years. The investigators will then compare data by Tanner stage to construct an integrated portrayal of the physiological changes that occur throughout puberty. Given the rarity of T2D prior to pubertal onset, the investigators chose to enroll a high high-risk group: youth with obesity and/or HbA1c ≥6.0% to represent youth ranging from those at magnified risk of developing T2D to those recently diagnosed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HbA1c ≥6.0% for untreated high-risk group
  • BMI ≥ 85th %ile for high-risk group
  • Normal HbA1c ≤5.6% for control group
  • Type 1 diabetes (T1D) Antibody negative

Exclusion criteria

  • History of Chronic kidney disease (CKD) or acute kidney injury (AKI)
  • Metabolic disorder prohibiting safe fasting
  • Iodine or penicillin allergy
  • Pregnancy
  • Thrombophilia
  • MRI contraindications
  • Hormone therapy

Treatment and study plan

Aminohippurate Sodium Inj 20%

Drug

Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Other names: Sodium 4-amino hippurate (PAH) inj 20% 2g/10mL, Para-aminohippurate, Aminohippuric acid

Iohexol Inj 300 mg/mL

Drug

Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Other names: omnipaque 300

Dextran 40

Drug

Diagnostic aid/agent used to measure glomerular size and selectivity

Other names: Dextran Sieving

Primary outcomes

  1. Effective renal plasma flow (ERPF)

    Time frame: 3 Hours

    Measured by PAH Clearance

  2. Glomerular Filtration Rate (GFR)

    Time frame: 3 hours

    Measured by iohexol clearance

Secondary outcomes

  1. Insulin Sensitivity

    Time frame: 3 hours

    Measured by IV glucose tolerance test (IVGTT)

  2. Renal perfusion

    Time frame: 10 min

    Arterial spin labeling (ASL) MRI

  3. Renal oxygenation

    Time frame: 60 min

    Blood oxygen level dependent (BOLD) MRI

Study contacts

Contact information is provided by the study sponsor or research team.

Petter Bjornstad, MD

CONTACT

[email protected]

(206) 616 3543

Sponsors and collaborators

Lead sponsor

Petter Bjornstad

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Seattle Children's Hospital
  • University of Colorado, Denver

Registry information

Official study title

PANTHER Study: Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Aug 17, 2021
Registry last updated
Mar 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.